AbbVie Qulipta Menstrual Migraine Win Sets Up Label Expansion

AbbVie scored a Phase 3 win for its migraine preventive Qulipta in a population that has no approved therapy. The drug reduced the number of migraine days during the perimenstrual period versus placebo, hitting the primary endpoint, and met all secondary goals including acute medication use and functional disability. AbbVie said no new safety signals emerged.

The trial positions Qulipta for a label expansion in menstrual migraine, a niche the company estimates covers more than nine million adult patients in the U.S. Roughly 12% of Americans experience migraines, and at least 60% of menstruating migraine patients report attacks around their cycle, AbbVie said. Actual penetration will depend on insurance coverage, physician adoption, and how many patients consider their symptoms severe enough for pharmaceutical management, but the data open a new revenue path.

Qulipta's sales have been accelerating. The drug generated $350 million in the second quarter, up 31% year over year, and $1 billion in all of 2024. Some analysts cited by Motley Fool expect peak sales to exceed $2 billion. Still, Qulipta is a smaller piece of AbbVie's revenue. Second-quarter total revenue reached $17 billion, up 10% year over year.

The company's main growth pillars remain the immunology drugs Skyrizi and Rinvoq. Management expects combined revenue from the two to surpass $31 billion this year. That target originally called for 2027, a deadline that had already been raised by $4 billion from an earlier forecast.

AbbVie recently added a late-stage pipeline asset to that franchise. It closed the $10.9 billion acquisition of Apogee Therapeutics in August, gaining zumilokibart, a candidate for eczema and other indications. Some analysts project peak sales of $5.2 billion in eczema alone, according to the Motley Fool article. The drug could become an heir to Skyrizi and Rinvoq as those drugs approach their own exclusivity windows.

AbbVie is also a Dividend King, having raised its payout for 50 consecutive years. The steady dividend growth and the immunology franchise support a consistent financial profile.

AbbVie carries an Alpha Score of 62, labeled Moderate, on AlphaScala's proprietary stock assessment. The score reflects the stable revenue base and concentration risk in its immunology portfolio. Full data from the menstrual migraine trial are expected at a future medical conference, AbbVie said.